Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List

Victory Square Technologies ranked No. 58 on Canada's Top Growing Companies list, reporting 497% revenue growth from 2022 to 2025 and the second-highest position among 24 publicly traded companies on the list. In H1 2026, consolidated revenue rose approximately 434% year over year to C$53.0 million from C$9.9 million, primarily due to its largest operating subsidiary, Hydreight; gross profit was C$10.5 million. The company reported C$20.2 million in cash and C$34.5 million in working capital as of June 30, 2026, while noting its other highlighted businesses are at earlier development stages.

Analysis

The key underwriting issue is earnings quality, not headline growth. From the supplied figures, consolidated gross margin fell to about 20% in H1 2026 from about 34% a year earlier, while gross profit grew much more slowly than revenue. That divergence warrants checking the mix, pricing, fulfillment costs and acquisition contribution before treating scale as evidence of improving economics. Hydreight is the principal revenue engine, so portfolio breadth should not be mistaken for diversified operating cash flow; a setback at that subsidiary could dominate the parent’s near-term results. For Hydreight (NURS), the parent’s recognition is at most a modest visibility tailwind, not evidence of incremental customer demand. The holding-company case also depends on whether investors can value and realize returns from private and development-stage assets; Insu’s delivery concept and Pawsible’s cohort remain execution and funding options, not current offsets to operating concentration. Near term, the October 8 webinar is a disclosure catalyst: concrete portfolio NAV methodology, capital allocation and segment economics matter more than promotional claims. Over 1–3 months, the next financial disclosure should test gross-margin direction and cash conversion. Over 6–18 months, sustained Hydreight unit economics and reduced dependence on one operating business would support a stronger look-through valuation. The contrarian point is that the growth accolade may overstate progress: the margin divergence and concentration are more decision-relevant than historical revenue rank.

Key Decisions for Investors

• Do not chase Victory Square on the ranking announcement alone. The supplied data do not establish valuation, segment profitability, debt, dilution or a realizable net asset value; review those items before taking parent-level exposure.
• Treat NURS as a watchlist name rather than a buy-through signal from its parent. Reassess after verifying Hydreight’s standalone revenue mix, gross-margin drivers, customer retention and cash conversion; improving margins alongside growth would strengthen the operating case.
• Use the October 8 webinar as a near-term diligence catalyst. Upgrade conviction only if management provides measurable portfolio valuation and capital-allocation detail; vague NAV claims or additional funding needs without operating milestones would reinforce a holding-company discount concern.
• Falsifiers: a further decline in consolidated gross margin or weak cash conversion would challenge the scale thesis; sustained margin recovery and evidence that revenue growth translates into cash generation would weaken the cautious view. No price-based trigger is supplied.